N
CADL icon

Nuveen’s Candel Therapeutics CADL Stock Holding History

Nuveen’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456K Buy
93,158
+676
+0.7% +$3.68K ﹤0.01% 2874
2025
Q4 		$523K Sell
92,482
-117,180
-56% -$630K ﹤0.01% 2853
2025
Q3 		$1.07M Buy
209,662
+117,180
+127% +$677K ﹤0.01% 2594
2025
Q2 		$468K Buy
92,482
+14,337
+18% +$73.8K ﹤0.01% 2906
2025
Q1 		$442K Buy
78,145
+9,919
+15% +$81K ﹤0.01% 2945
2024
Q4 		$592K Buy
68,226
+2,009
+3% +$11.9K ﹤0.01% 2926
2024
Q3 		$459K Sell
66,217
-315,971
-83% -$1.96M ﹤0.01% 3045
2024
Q2 		$2.37M Buy
+382,188
New +$2.87M ﹤0.01% 2299

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's CADL Position: Q1 2026 in Review

Nuveen increased its Candel Therapeutics (CADL) stake by 0.73% in Q1 2026, buying an estimated $3.68K and bringing the position to 93,158 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #2874.

Nuveen first reported a position in CADL in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.37M in Q2 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Nuveen held 93,158 shares of Candel Therapeutics worth $456K as of Q1 2026.
  • Nuveen bought 676 Candel Therapeutics shares in Q1 2026, an estimated $3.68K.
  • Candel Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2874 holding.
  • Nuveen first reported a position in Candel Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Nuveen's Candel Therapeutics position peaked at $2.37M in Q2 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.